D-18F-fluoromethyl tyrosine imaging of bone metastases in a mouse model

Journal of Nuclear Medicine

Volumn 51, Issue 10, 2010, Pages 1632-1636

  Zitzmann Kolbe, Sabine ^a   Strube, Anne ^a   Frisk, Anna Lena ^a   Käkönen, Sanna Maria ^a,b   Tsukada, Hideo ^c   Hauff, Peter ^a   Berndorff, Dietmar ^a   Graham, Keith ^a  

^a BAYER PHARMA AG   (Germany)

^b UNIVERSITY OF TURKU   (Finland)

^c HAMAMATSU PHOTONICS K K   (Japan)

Author keywords

18F fluoride; Bone metastases; D 18F FMT; Imaging; PET CT; Tyrosine

Indexed keywords

FLUORINE 18; FLUOROMETHYLTYROSINE F 18; TRACER; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; DRUG DERIVATIVE; O (18F)FLUOROMETHYL L TYROSINE; O-(18F)FLUOROMETHYL-L-TYROSINE; RADIOPHARMACEUTICAL AGENT; TYROSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL CIRCULATION; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER CELL CULTURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DRUG SYNTHESIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; KIDNEY CARCINOMA; MOUSE; NONHUMAN; OSTEOLYSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; ANIMAL; BONE TUMOR; DISEASE MODEL; FEMALE; METASTASIS; NUDE MOUSE; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TUMOR CELL LINE;

ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; MICE, NUDE; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TYROSINE;

EID: 79851470834     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.078899     Document Type: Article

References (21)

1. Chua S, Gnanasegaran G, Cook GJ. Miscellaneous cancers (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors): role of SPECT and PET in imaging bone metastases. Semin Nucl Med. 2009;39:416-430.
2. Christensen HN. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev. 1990;70:43-77. (Pubitemid 20037281)
3. Yanagida O, Kanai Y, Chairoungdua A, et al. Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta. 2001;1514:291-302. (Pubitemid 32831016)
4. Lindholm P, Lapela M, Nagren K, Lehikoinen P, Minn H, Jyrkkio S. Preliminary study of carbon-11 methionine PET in the evaluation of early response to therapy in advanced breast cancer. Nucl Med Commun. 2009;30:30-36.
5. 11C-methionine PET and bone scintigraphy. Magn Reson Imaging. 2010;28:372-379.
6. Kobayashi H, Ishii Y, Takayama T. Expression of L-type amino acid transporter 1 (LAT1) in esophageal carcinoma. J Surg Oncol. 2005;90:233-238. (Pubitemid 40770938)
7. Nawashiro H, Otani N, Shinomiya N, et al. L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer. 2006;119:484-492. (Pubitemid 43955699)
8. Kaira K, Oriuchi N, Imai H, et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer. 2008;98:742-748. (Pubitemid 351272621)
9. 18F] fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol. 2006;33:287-294.
10. 18F-FDG PET-CT: a clinicopathological study. Int J Cancer. 2009;124:1152-1160.
11. 18F-fluoroethyl and O-18F-fluoropropyl tyrosine as tumour imaging agents in mice. Eur J Nucl Med Mol Imaging. 2006;33:1017-1024.
12. 18F-fluoromethyl tyrosine as tumor-imaging agents in tumor-bearing mice: comparison with L- and D-11C-methionine. J Nucl Med. 2006;47:679-688.
13. 123I-2-iodo-D-phenylalanine, a new potential tumor-specific tracer for SPECT, in an R1M rhabdomyosarcoma athymic mouse model. J Nucl Med. 2005;46:2104-2111.
14. 18F]fluoromethyl-d-tyrosine as a radiotracer for tumor imaging with positron emission tomography. Nucl Med Biol. 2009;36:295-303.
15. 18F-FLT for monitoring the response of tumors to radiotherapy in mice. J Nucl Med. 2009;50:290-295.
16. Strube A, Stepina E, Hartmann B, Neumann I, Hauff P, Kaekoenen S. P14. Development and characterization of a new renal cell carcinoma (RCC) bone metastasis mouse model. Cancer Treat Rev. 2008;34(suppl 1):17.
17. Strube A, Stepina E, Mumberg D, Scholz A, Hauff P, Kakonen SM. Characterization of a new renal cell carcinoma bone metastasis mouse model. Clin Exp Metastasis. 2010;27:319-330.
18. 18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med. 1999;40:205-212.
19. Schirrmeister H. Detection of bone metastases in breast cancer by positron emission tomography. Radiol Clin North Am. 2007;45:669-676. (Pubitemid 47238392)
20. Berger F, Lee YP, Loening AM, et al. Whole-body skeletal imaging in mice utilizing microPET: optimization of reproducibility and applications in animal models of bone disease. Eur J Nucl Med Mol Imaging. 2002;29:1225-1236. (Pubitemid 34985371)
21. Franzius C, Hotfilder M, Poremba C, et al. Successful high-resolution animal positron emission tomography of human Ewing tumours and their metastases in a murine xenograft model. Eur J Nucl Med Mol Imaging. 2006;33:1432-1441. (Pubitemid 44885409)